These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 38008684)

  • 21. The effect of elexacaftor/tezacaftor/ivacaftor (ETI) on glycemia in adults with cystic fibrosis.
    Scully KJ; Marchetti P; Sawicki GS; Uluer A; Cernadas M; Cagnina RE; Kennedy JC; Putman MS
    J Cyst Fibros; 2022 Mar; 21(2):258-263. PubMed ID: 34531155
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of elexacaftor/tezacaftor/ivacaftor on respiratory colonization in an adult cystic fibrosis clinic.
    Szabo MM; Foushee SE; McPheeters CM; O'Hagan AR; Ramirez AM; O'Reilly EA
    Am J Med Sci; 2024 May; 367(5):337-342. PubMed ID: 38336262
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of elexacaftor/tezacaftor/ivacaftor on airway and systemic inflammation in cystic fibrosis.
    Casey M; Gabillard-Lefort C; McElvaney OF; McElvaney OJ; Carroll T; Heeney RC; Gunaratnam C; Reeves EP; Murphy MP; McElvaney NG
    Thorax; 2023 Aug; 78(8):835-839. PubMed ID: 37208188
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Influence of highly effective modulator therapy on the sputum proteome in cystic fibrosis.
    Maher RE; Barry PJ; Emmott E; Jones AM; Lin L; McNamara PS; Smith JA; Lord RW
    J Cyst Fibros; 2024 Mar; 23(2):269-277. PubMed ID: 37951788
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Use of cystic fibrosis inhaled medication before and after elexacaftor/tezacaftor/ivacaftor initiation.
    Manika K; Diamantea F; Tsakona A; Kakolyris A; Sopiadou A; Kotoulas SC; Sionidou M; Kirvasili SS; Hadji-Mitrova M; Papadaki E; Chrysochoou EA; Hatziagorou E
    J Cyst Fibros; 2024 Jan; 23(1):29-31. PubMed ID: 37169616
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of elexacaftor-tezacaftor-ivacaftor on bacterial colonization and inflammatory responses in cystic fibrosis.
    Sheikh S; Britt RD; Ryan-Wenger NA; Khan AQ; Lewis BW; Gushue C; Ozuna H; Jaganathan D; McCoy K; Kopp BT
    Pediatr Pulmonol; 2023 Mar; 58(3):825-833. PubMed ID: 36444736
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele.
    Middleton PG; Mall MA; Dřevínek P; Lands LC; McKone EF; Polineni D; Ramsey BW; Taylor-Cousar JL; Tullis E; Vermeulen F; Marigowda G; McKee CM; Moskowitz SM; Nair N; Savage J; Simard C; Tian S; Waltz D; Xuan F; Rowe SM; Jain R;
    N Engl J Med; 2019 Nov; 381(19):1809-1819. PubMed ID: 31697873
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Longitudinal profiling of the intestinal microbiome in children with cystic fibrosis treated with elexacaftor-tezacaftor-ivacaftor.
    Reasoner SA; Bernard R; Waalkes A; Penewit K; Lewis J; Sokolow AG; Brown RF; Edwards KM; Salipante SJ; Hadjifrangiskou M; Nicholson MR
    mBio; 2024 Feb; 15(2):e0193523. PubMed ID: 38275294
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Exploring the impact of elexacaftor-tezacaftor-ivacaftor treatment on opinions regarding airway clearance techniques and nebulisers: TEMPO a qualitative study in children with cystic fibrosis, their families and healthcare professionals.
    Almulhem M; Harnett N; Graham S; Haq I; Visram S; Ward C; Brodlie M
    BMJ Open Respir Res; 2022 Oct; 9(1):. PubMed ID: 36207030
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Eradication of Mycobacterium abscessus infection in cystic fibrosis with initiation of Elexacaftor/Tezacaftor/Ivacaftor.
    McParland C; Nunn M; Marras TK; Chiasson M
    J Cyst Fibros; 2024 Jan; 23(1):38-40. PubMed ID: 37076409
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chest computed tomography improvement in patients with cystic fibrosis treated with elexacaftor-tezacaftor-ivacaftor: Early report.
    Bec R; Reynaud-Gaubert M; Arnaud F; Naud R; Dufeu N; Di Bisceglie M; Coiffard B; Gaubert JY; Bermudez J; Habert P
    Eur J Radiol; 2022 Sep; 154():110421. PubMed ID: 35772339
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of chronic medication de-escalation in patients with cystic fibrosis taking elexacaftor, tezacaftor, ivacaftor: A retrospective review.
    Guenther EL; McCoy KS; Eisner M; Bai S; Nemastil CJ; Novak KJ; Johnson T; Stephan EM
    J Cyst Fibros; 2024 Jan; 23(1):32-37. PubMed ID: 37069044
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Longitudinal Evaluation of Bronchial Changes in Cystic Fibrosis Patients Undergoing Elexacaftor/Tezacaftor/Ivacaftor Therapy Using Lung MRI With Ultrashort Echo-Times.
    David M; Benlala I; Bui S; Benkert T; Berger P; Laurent F; Macey J; Dournes G
    J Magn Reson Imaging; 2024 Jul; 60(1):116-124. PubMed ID: 37861357
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Longitudinal microbial and molecular dynamics in the cystic fibrosis lung after Elexacaftor-Tezacaftor-Ivacaftor therapy.
    Martin C; Guzior DV; Gonzalez CT; Okros M; Mielke J; Padillo L; Querido G; Gil M; Thomas R; McClelland M; Conrad D; Widder S; Quinn RA
    Respir Res; 2023 Dec; 24(1):317. PubMed ID: 38104128
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Patient perspectives following initiation of elexacaftor-tezacaftor-ivacaftor in people with cystic fibrosis and advanced lung disease.
    Martin C; Burnet E; Ronayette-Preira A; de Carli P; Martin J; Delmas L; Prieur B; Burgel PR
    Respir Med Res; 2021 Nov; 80():100829. PubMed ID: 34091202
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Elexacaftor/tezacaftor/ivacaftor influences body composition in adults with cystic fibrosis: a fully automated CT-based analysis.
    Westhölter D; Haubold J; Welsner M; Salhöfer L; Wienker J; Sutharsan S; Straßburg S; Taube C; Umutlu L; Schaarschmidt BM; Koitka S; Zensen S; Forsting M; Nensa F; Hosch R; Opitz M
    Sci Rep; 2024 Apr; 14(1):9465. PubMed ID: 38658613
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment effects of Elexacaftor/Tezacaftor/Ivacaftor in people with CF carrying non-F508del mutations.
    Livnat G; Dagan A; Heching M; Shmueli E; Prais D; Yaacoby-Bianu K; Stein N; Mei-Zahav M; Gur M; Cohen-Cymberknoh M; Shteinberg M
    J Cyst Fibros; 2023 May; 22(3):450-455. PubMed ID: 36372699
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Changes in liver biochemistry and tacrolimus levels following the introduction of elexacaftor/tezacaftor/ivacaftor in patients with cystic fibrosis and liver transplant.
    Tachtatzis P; Spoletini G; Clifton I; Etherington C; Peckham D
    J Cyst Fibros; 2024 Jan; 23(1):99-102. PubMed ID: 37164896
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Onset of systemic arterial hypertension after initiation of elexacaftor/tezacaftor/ivacaftor in adults with cystic fibrosis: A case series.
    Gramegna A; De Petro C; Leonardi G; Contarini M; Amati F; Meazza R; Carugo S; Blasi F
    J Cyst Fibros; 2022 Sep; 21(5):885-887. PubMed ID: 35450770
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Case Series: Hyperbilirubinemia under elexacaftor/tezacaftor/ivacaftor in the presence of Gilbert's syndrome.
    Weitzel J; Welsner M; Taube C; Ballmann M; Sutharsan S
    BMC Pulm Med; 2024 Jul; 24(1):307. PubMed ID: 38956524
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.